Physical activity habits in early Parkinson’s disease and healthy controls
Objective: Investigate the physical activity habits of Parkinson’s disease (PD) and healthy control (HC) participants of the PPMI cohort. Background: Exercise can improve the motor…Identification of a trehalose treatment regimen with potential to be translated into a therapeutic for the treatment of Parkinson’s disease
Objective: To evaluate the preclinical efficacy of trehalose and to identify a dosing regimen that can be used to clinically evaluate trehalose as a disease-modifying therapy…Clinical and Imaging and phenoconversion in the PARS prodromal cohort
Objective: We report clinical and imaging phenoconversion data at 6 years follow-up for the PARS cohort. Background: The PARS cohort consists of 203 hyposmic and…Neuroprotective effects of antidepressant mirtazapine against dopaminergic neurodegeneration in cultured cells and in parkinsonian mice possibly by targeting astrocytes
Objective: In this study, we examined neuroprotective effects of mirtazapine and involvement of astrocytes in the effects using primary cultured cells and parkinsonian mice. Background:…Higher genetic load is associated with an earlier disease onset but not with more rapid disease progression in Parkinson’s disease
Objective: To evaluate the influence of genetic variants on phenotypic variability and disease progression in PD patients. Background: Parkinson’s disease (PD) patients show a large…The Corticobasal Degeneration Functional Rating Scale (CBD-FS)
Objective: To develop a patient/care giver-reported scale that is capable of assessing functional disability in CBD that can be easily and reliably used in clinical…WTX101 – A Novel Copper Modulating Agent for Wilson Disease Demonstrates Efficacy and Safety in a Phase 2, Multi-Center, Open Label Study
Objective: The objective of this study was to evaluate the efficacy and safety of 24 week WTX101 treatment in newly diagnosed Wilson Disease (WD) patients. Background:…Human-derived α-synuclein antibody BIIB054 binds pathologic forms of α-synuclein and attenuates transmission of α-synuclein in vitro and in vivo
Objective: To identify and characterize a human antibody against α-synuclein (α-syn) for the clinical development of an immunotherapy for Parkinson's disease (PD). Background: α-syn plays…Novel small molecules targeting alpha-synuclein aggregation for the treatment of Parkinson’s disease
Objective: To develop novel, small molecular weight compounds, that can interfere with the aggregation process of alpha-synuclein (aSyn), as disease modifying agents. Background: The aggregation…Critical path for Parkinson’s, I: Data sharing and regulatory science in catalyzing innovation for Parkinson’s disease
Objective: This presentation highlights a new precompetitive consortium based strategy for the successful development of regulatory-endorsed biomarkers and quantitative drug development platforms targeted at the…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.